Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

Chief Financial Officer

Chief Executive Officer

Chief Legal Officer

Chief Scientific Officer

Chief Business Officer

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 that is in Phase I of clinical trial for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-204 that is in Phase I for the treatment of solid tumors. The company also developing TSC-200, TSC-201, TSC-202, TSC-203, and TSC-205 for the treatment of solid tumors. In addition, it engages in the developing vaccines for infectious diseases, such as SARS-CoV-2. The company has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer; and a collaboration agreement with Amgen to identify novel targets in Crohn's disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatme...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2023-12-19	Premium	bought	Premium	Premium	Premium	-
2023-12-18	Premium	bought	Premium	Premium	Premium	-
2023-12-14	Premium	bought	Premium	Premium	Premium	-
2023-06-02	Premium	bought	Premium	Premium	Premium	-
2023-05-31	Premium	sold	Premium	Premium	Premium	-
2023-05-31	Premium	sold	Premium	Premium	Premium	-
2022-12-28	Premium	bought	Premium	Premium	Premium	Chief Financial Officer
2022-12-27	Premium	bought	Premium	Premium	Premium	Chief Financial Officer
2022-05-18	Premium	bought	Premium	Premium	Premium	Chief Executive Officer
2022-05-11	Premium	bought	Premium	Premium	Premium	-
2022-05-10	Premium	bought	Premium	Premium	Premium	-
2022-03-24	Premium	bought	Premium	Premium	Premium	Chief Financial Officer
2021-12-23	Premium	acquired	Premium	Premium	Premium	Chief Executive Officer
2021-09-23	Premium	bought	Premium	Premium	Premium	Chief Legal Officer
2021-09-21	Premium	bought	Premium	Premium	Premium	Chief Scientific Officer
2021-09-21	Premium	bought	Premium	Premium	Premium	Chief Financial Officer
2021-09-20	Premium	bought	Premium	Premium	Premium	Chief Scientific Officer
2021-09-09	Premium	bought	Premium	Premium	Premium	Chief Financial Officer
2021-09-08	Premium	bought	Premium	Premium	Premium	Chief Executive Officer
2021-08-27	Premium	bought	Premium	Premium	Premium	Chief Business Officer
2021-07-20	Premium	bought	Premium	Premium	Premium	Chief Financial Officer
2021-07-20	Premium	acquired	Premium	Premium	Premium	-
2021-07-20	Premium	bought	Premium	Premium	Premium	-
2021-07-20	Premium	bought	Premium	Premium	Premium	-
2021-07-20	Premium	acquired	Premium	Premium	Premium	-

TCRX - TScan Therapeutics, Inc. Stock Price, Fair Value and News

Latest Insider Trading transactions for TCRX